Mike Brooks
Vice President
Mike Brooks is a Vice President at PMCF Investment Banking and serves on the team’s Healthcare & MedTech team. He has more than a decade of professional experience advising public and private companies on buy-side and sell-side M&A mandates, recapitalizations, debt and equity financings, transaction planning assessments and strategic consulting. He has extensive experience across healthcare, business services and industrials sectors.
Prior to joining PMCF, Mike worked as an analyst at a boutique investment bank, focusing on providing financial and strategic analysis, valuation, industry research, due diligence, and preparation of comprehensive client marketing materials. A native of Chicago, Mike earned a BBA in Finance from the University of Iowa. He is a licensed securities representative holding his Series 79 and 63 registrations.
Transaction Experience
PMCF Advises CLM Enterprises, Inc. on its Sale to an Employee Stock Ownership Plan
PMCF Advises Airsupply Jeyco in its Sale to Tide Rock
PMCF Advises Raland Compliance Partners in its Sale to Akkodis, A Global Digital Engineering Company and Part of The Adecco Group
PMCF Advises EZ Concrete Supply in its Sale to Aramsco, an Odyssey Portfolio Company
PMCF Advises Century in its Sale Transaction to Hillcrest Investment Partners
PMCF Advises Marcus Thomas in a Recapitalization Transaction with Svoboda Capital Partners
PMCF Advises Master Automatic in its Majority Sale Transaction to MacLean-Fogg Component Solutions
PMCF advises Great Lakes Trim, Inc in its sale transaction to GLT GLIF, Inc.
Publications
2026 Medtech M&A Outlook Strengthens as Buyers Prioritize Innovation and Resilience
Medtech is entering 2026 with a healthier M&A environment supported by improved financing conditions, resilient sector performance, and a more straightforward path for strategic buyers and private equity.
Medical Technology M&A Pulse – Q3 2025
M&A activity in the Medical Technology sector remained subdued in Q3 2025 at 102 announced transactions, significantly below the 165 deals recorded in Q3 2024.
Tariffs & Workforce Talent: Two Factors Shaping Healthcare M&A in 2025
Tariffs and staffing stability remain key factors shaping healthcare and MedTech M&A in 2025.
Medical Technology M&A Pulse – Q2 2025
M&A activity in the Medical Technology sector remained subdued in Q2 2025, with 104 announced transactions, a decline from the 128 deals recorded in Q2 2024.
How AI Continues To Drive MedTech M&A
Capital continues to flow into MedTech M&A as companies pursue AI-driven solutions to streamline administrative tasks and drive improved patient outcomes.